Intraintestinal administration of ulinastatin protects against sepsis by relieving intestinal damage

Journal of Surgical Research

Volumn 211, Issue , 2017, Pages 70-78

  Yang, Bingchang ^a,b   Gao, Min ^a,b   Wang, Kangkai ^a,b   Jiang, Yu ^a,b   Peng, Yue ^a   Zhang, Huali ^a,b   Yang, Mingshi ^a,b   Xiao, Xianzhong ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

Intestinal protection; Intraintestinal administration; Sepsis; Ulinastatin

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTIC ACID; TUMOR NECROSIS FACTOR; ULINASTATIN; BIOLOGICAL MARKER; GLYCOPROTEIN; TRYPSIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CONTROLLED STUDY; DUODENUM FISTULA; INTESTINE INJURY; INTESTINE TISSUE; INTRAINTESTINAL DRUG ADMINISTRATION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SEPSIS; ULTRASTRUCTURE; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; INTESTINE; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; PATHOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; GLYCOPROTEINS; INJECTIONS, INTRAPERITONEAL; INTESTINES; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; TREATMENT OUTCOME; TRYPSIN INHIBITORS;

EID: 85007593377     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2016.11.061     Document Type: Article

References (32)

1. 1 Singer, M., Deutschman, C.S., Seymour, C.W., et al. The Third international Consensus Definitions for sepsis and septic shock (Sepsis-3). JAMA 315 (2016), 801–810.
2. 2 Fry, D.E., Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg 78 (2012), 1–8.
3. 3 Angus, D.C., van der Poll, T., Severe sepsis and septic shock. N Engl J Med 369 (2013), 840–851.
4. 4 Deutschman, C.S., Tracey, K.J., Sepsis: current dogma and new perspectives. Immunity 40 (2014), 463–475.
5. 5 Schortgen, F., Asfar, P., Update in sepsis and acute kidney injury 2014. Am J Respir Crit Care Med 191 (2015), 1226–1231.
6. 6 Cho, W.H., Update of sepsis: recent evidences about early goal directed therapy. Tuberc Respir Dis (Seoul) 78 (2015), 156–160.
7. 7 Dombrovskiy, V.Y., Martin, A.A., Sunderram, J., Paz, H.L., Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35 (2007), 1244–1250.
8. 8 Nishiyama, T., Aibiki, M., Hanaoka, K., The effect of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymorphonuclear granulocyte elastase. Anesth Analg 82 (1996), 108–112.
9. 9 Tsujino, T., Komatsu, Y., Isayama, H., et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 3 (2005), 376–383.
10. 10 Yoo, J.W., Ryu, J.K., Lee, S.H., et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial. Pancreas 37 (2008), 366–370.
11. 11 Deitch, E.A., Gut-origin sepsis: evolution of a concept. Surgeon 10 (2012), 350–356.
12. 12 Li, Q., Zhang, Q., Wang, C., et al. Disruption of tight junctions during polymicrobial sepsis in vivo. J Pathol 218 (2009), 210–221.
13. 13 Dominguez, J.A., Samocha, A.J., Liang, Z., et al. Inhibition of IKKbeta in enterocytes exacerbates sepsis-induced intestinal injury and worsens mortality. Crit Care Med 41 (2013), e275–e285.
14. 14 Magnotti, L.J., Deitch, E.A., Burns, bacterial translocation, gut barrier function, and failure. J Burn Care Rehabil 26 (2005), 383–391.
15. 15 Vaishnavi, C., Translocation of gut flora and its role in sepsis. Indian J Med Microbiol 31 (2013), 334–342.
16. 16 Schmid-Schonbein, G.W., Biomechanical aspects of the auto-digestion theory. Mol Cell Biomech 5 (2008), 83–95.
17. 17 Chiu, C.J., McArdle, A.H., Brown, R., Scott, H.J., Gurd, F.N., Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 101 (1970), 478–483.
18. 18 Ueki, M., Taie, S., Chujo, K., et al. Urinary trypsin inhibitor reduces inflammatory response in kidney induced by lipopolysaccharide. J Biosci Bioeng 104 (2007), 315–320.
19. 19 Takano, H., Inoue, K., Shimada, A., Sato, H., Yanagisawa, R., Yoshikawa, T., Urinary trypsin inhibitor protects against liver injury and coagulation pathway dysregulation induced by lipopolysaccharide/D-galactosamine in mice. Lab Invest 89 (2009), 833–839.
20. 20 Gao, C., Liu, Y., Ma, L., Wang, S., Protective effects of ulinastatin on pulmonary damage in rats following scald injury. Burns 38 (2012), 1027–1034.
21. 21 Inoue, K., Takano, H., Sato, H., Yanagisawa, R., Yoshikawa, T., Protective role of urinary trypsin inhibitor in lung expression of proinflammatory cytokines accompanied by lethal liver injury in mice. Immunopharmacol Immunotoxicol 31 (2009), 446–450.
22. 22 Lee, J.Y., Lee, J.Y., Chon, J.Y., Moon, H.S., Hong, S.J., The effect of ulinastatin on hemostasis in major orthopedic surgery. Korean J Anesthesiol 58 (2010), 25–30.
23. 23 Fang, Y., Xu, P., Gu, C., Wang, Y., Fu, X.J., et al. Ulinastatin improves pulmonary function in severe burn-induced acute lung injury by attenuating inflammatory response. J Trauma 71 (2011), 1297–1304.
24. 24 Catalioto, R.M., Maggi, C.A., Giuliani, S., Intestinal epithelial barrier dysfunction in disease and possible therapeutical interventions. Curr Med Chem 18 (2011), 398–426.
25. 25 Dellinger, R.P., Levy, M.M., Rhodes, A., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41 (2013), 580–637.
26. 26 Mitsuoka, H., Kistler, E.B., Schmid-Schonbein, G.W., Generation of in vivo activating factors in the ischemic intestine by pancreatic enzymes. Proc Natl Acad Sci U S A 97 (2000), 1772–1777.
27. 27 Mitsuoka, H., Kistler, E.B., Schmid-Schonbein, G.W., Protease inhibition in the intestinal lumen: attenuation of systemic inflammation and early indicators of multiple organ failure in shock. Shock 17 (2002), 205–209.
28. 28 Doucet, J.J., Hoyt, D.B., Coimbra, R., et al. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock. J Trauma 56 (2004), 501–510 510-511.
29. 29 Wang, N., Liu, X., Zheng, X., et al. Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol 17 (2013), 799–807.
30. 30 Lin, S., Huang, Z., Wang, M., et al. Interleukin-6 as an early diagnostic marker for bacterial sepsis in patients with liver cirrhosis. J Crit Care 30 (2015), 732–738.
31. 31 Puneet, P., Yap, C.T., Wong, L., et al. SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 328 (2010), 1290–1294.
32. 32 Weber, G.F., Chousterman, B.G., He, S., et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 347 (2015), 1260–1265.